The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC

Treating pancreatic ductal adenocarcinoma (PDAC) remains a major hurdle in the field of oncology. Less than half of patients respond to frontline chemotherapy and the pancreatic tumor microenvironment limits the efficacy of immunotherapeutic approaches. Targeted therapies could serve as effective tr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: Brown, Matthew, Zhang, Wanbin, Yan, Deyue, Kenath, Rajath, Le, Le, Wang, He, Delitto, Daniel, Ostrov, David, Robertson, Keith, Liu, Chen, Pham, Kien
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6957139/
https://ncbi.nlm.nih.gov/pubmed/31929540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0226917
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares